The American Society of Hematology (ASH) 2014 annual meeting will take place on December 5–9, 2014. As a preview for our BioMedTracker ASH meeting coverage, we provide a graphical overview of epidemiology and the drug development space in hematology-oncology. Several drugs were approved in the last year to treat blood cancers, including the first-in-class drugs Imbruvica (PCYC/JNJ), Zydelig (GILD), and Sylvant (JNJ). Drug candidates in the pipeline today may eventually transform the treatment of ALL, AML, and other blood cancers.

This infographic also provides a summary of key data presentations for blood cancers at the ASH meeting. Drug candidates with exciting new or updated data include: blinatumomab (AMGN), daratumumab (JNJ), Opdivo (nivolumab; BMY), inotuzumab ozogamacin (PFE), and ABT-199/venetoclax (ABBV).

To download a copy of this infographic, click on the link at the top of the page. Additional ASH- and oncology-related special reports available to BioMedTracker subscribers are linked at the bottom of the page.

For our disclosures, please read the BioMedTracker Research Standards.